Immediate Impact
50 standout
Citing Papers
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Works of Sanjeev Deva being referenced
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Sanjeev Deva | 172 | 59 | 64 | 61 | 36 | 240 | |
| Sara Delfanti | 112 | 90 | 42 | 57 | 31 | 242 | |
| Radheshyam Naik | 140 | 78 | 66 | 40 | 56 | 250 | |
| Blessie Elizabeth Nelson | 110 | 44 | 55 | 53 | 33 | 207 | |
| Matthias Zaiß | 94 | 58 | 50 | 49 | 34 | 256 | |
| Ece Esin | 145 | 57 | 28 | 62 | 30 | 293 | |
| Ying Cheng | 194 | 88 | 30 | 55 | 46 | 235 | |
| Annelieke E.C.A.B. Willemsen | 139 | 100 | 37 | 89 | 25 | 288 | |
| Lokanatha Dasappa | 97 | 32 | 45 | 36 | 36 | 233 | |
| Mikiya Ishihara | 139 | 33 | 98 | 64 | 34 | 223 | |
| Μaria Anastasiou | 141 | 87 | 46 | 71 | 39 | 286 |
All Works
Login with ORCID to disown or claim papers
Loading papers...